BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18400265)

  • 1. Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer?
    Zapatero A; García-Vicente F; Sevillano D; Martín de Vidales C; Ferrer C; Torres JJ; Minguez R; Rabadán M
    Urology; 2008 Nov; 72(5):1130-4. PubMed ID: 18400265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.
    Devisetty K; Zorn KC; Katz MH; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1060-5. PubMed ID: 20045267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?
    Zapatero A; Ríos P; Marín A; Mínguez R; García-Vicente F
    Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):600-7. PubMed ID: 17051950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection.
    Sandhu AS; Zelefsky MJ; Lee HJ; Lombardi D; Fuks Z; Leibel SA
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):643-7. PubMed ID: 11020559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.
    Liu M; Pickles T; Agranovich A; Berthelet E; Duncan G; Keyes M; Kwan W; McKenzie M; Morris J; Pai H; Tyldesley S; Wu J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):59-67. PubMed ID: 14697421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.
    Sanguineti G; Agostinelli S; Foppiano F; Franzone P; Garelli S; Marcenaro M; Orsatti M; Vitale V
    Br J Cancer; 2002 Jun; 86(12):1843-7. PubMed ID: 12085173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
    Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response.
    Skwarchuk MW; Jackson A; Zelefsky MJ; Venkatraman ES; Cowen DM; Levegrün S; Burman CM; Fuks Z; Leibel SA; Ling CC
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):103-13. PubMed ID: 10758311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
    Valicenti RK; Winter K; Cox JD; Sandler HM; Bosch W; Vijayakumar S; Michalski J; Purdy J
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):614-20. PubMed ID: 14529764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal radiotherapy of organ-confined prostate cancer: the experience of the European Institute of Oncology.
    Greco C; Castiglioni S; Fodor A; Mazzetta C; De Cobelli O; Orecchia R
    Tumori; 2004; 90(6):567-72. PubMed ID: 15762358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters.
    Stankovic V; Džamic Z; Pekmezovic T; Tepavcevic DK; Dozic M; Saric M; Vuckovic S; Nikitovic M
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):577-86. PubMed ID: 27184943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
    Sanguineti G; Marcenaro M; Franzone P; Foppiano F; Vitale V
    Radiother Oncol; 2003 Feb; 66(2):151-7. PubMed ID: 12648786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.